Opinion|Videos|July 22, 2024
Is Clearance of ctDNA an Acceptable Surrogate End Point?
Author(s)Stacey A. Cohen, MD, Daniel H. Ahn, DO
Medical oncologists discuss whether ctDNA clearance can serve as an acceptable surrogate end point in the treatment of patients with colorectal cancer.
Advertisement
Episodes in this series
Advertisement
Related to this article
The FDA cleared the Triton 1 robotic endoscopy system for diagnostic and therapeutic procedures such as colorectal cancer screening and lesion removal.
The FDA granted fast track designation to the oral pan-KRAS inhibitor KST-6051 for patients with KRAS-mutant advanced or metastatic solid tumors.
The FDA has set a new action date of March 3, 2027, for zanzalintinib/atezolizumab for previously treated metastatic colorectal cancer.
The FDA withdrew accelerated approval for adagrasib/cetuximab in KRAS G12C-mutated colorectal cancer after the KRYSTAL-10 trial failed to improve survival.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves sNDA for Taletrectinib in TKI-Naive Advanced ROS1+ NSCLC
2
FDA Clears Triton Robotic Endoscopy System for Colon Procedures
3
ASTRO Issues First Clinical Practice Guideline on Radiation for Bladder Cancer
4
KST-6051 Receives FDA Fast Track Designation in KRAS-Mutant Solid Tumors
5